Rare diseases
Investigational molecules
Locations
Baeckerstrasse 4, Pasing-Obermenzing, 81241 Munich, Germany
Haematologie und Onkologie Muenchen-Pasing MVZ GmbH in Munich, Germany specialises in clinical trials of conditions such as Waldenstrom's macroglobulinaemia, Breast cancer female, Chronic lymphocytic leukaemia, Chronic myeloid leukaemia, and other specialisations. This site conducts important research.
The medical center is at the forefront of research in Waldenström’s Macroglobulinemia, focusing on innovative therapeutic combinations to enhance patient outcomes.
These studies aim to improve progression-free survival rates and explore the efficacy of novel drug combinations, offering new hope for patients with this rare condition.
In the field of Multiple Myeloma, the center is pioneering research to evaluate the effectiveness of advanced drug regimens in relapsed or refractory cases.
By comparing progression-free survival rates, the center aims to establish more effective treatment protocols for patients with challenging disease profiles.
Research in Chronic Myeloid Leukemia is focused on assessing the tolerability and efficacy of novel oral therapies for newly diagnosed patients.
The goal is to optimize treatment regimens by minimizing adverse events and improving patient adherence to therapy.
The center is advancing the understanding of Chronic Lymphocytic Leukemia through studies on the safety and tolerability of targeted monotherapies.
This research is crucial for developing safer, more effective treatment options for both treatment-naive and relapsed/refractory patients.
In the realm of Follicular Lymphoma, the center is exploring the benefits of combining novel immunotherapies with established treatments.
These efforts aim to enhance progression-free survival and offer new therapeutic avenues for patients with previously untreated conditions.
Research on Myelodysplastic Syndromes is focused on improving hematologic outcomes for patients with lower-risk profiles.
The center's work seeks to provide transfusion independence and improve quality of life for patients with anemia due to MDS.
Clinical trials currently enrolling participants at this site.
Study on Venetoclax and Rituximab for Patients with Waldenström’s Macroglobulinemia
GermanyStudy on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer
GermanyStudy of luspatercept in patients with low-risk myelodysplastic syndrome (MDS) who do not require blood transfusions and have not received erythropoiesis treatment
GermanyGermanyStudy of Acalabrutinib for Patients with Chronic Lymphocytic Leukemia
GermanyStudy on the Tolerability and Efficacy of Asciminib vs. Nilotinib for Adults with Newly Diagnosed Philadelphia Chromosome Positive Chronic Myeloid Leukemia
GermanyStudy to Compare Mezigdomide, Carfilzomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
GermanyStudy on Carfilzomib and Ibrutinib for Patients with Waldenström’s Macroglobulinemia
GermanyStudy on the Effectiveness of Bortezomib, Rituximab, and Ibrutinib for Patients with Newly Diagnosed Waldenström’s Macroglobulinemia
GermanyGet verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.
See the offer for sitesTell us about your condition – we search every trial in Europe and connect you with the right site.
